Salute e Benessere

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver…

GENFIT highlighted new focus and development strategy in Acute On-Chronic Liver Failure (ACLF)ACLF is a very serious condition affecting ~294,000 12patients with chronic liver diseases in the USA and Europe every year and is associated with multi-organ failure and high short-term mortalityIt is an underserved medical condition with currently no approved treatment and few programs under development globallyGENFIT has developed a unique pipeline of 5 different drug...
Nasdaq GlobeNewswire
16/11/2023

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Company announcement – No. 39 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, November 16, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 26,637 divided into 26,637 new shares with a nominal value of DKK 1...
Nasdaq GlobeNewswire
16/11/2023

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 07.00 PM CET– In...
Nasdaq GlobeNewswire
16/11/2023

Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program   Total of…

Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has received EUR 1.0 million in funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”).This is the third installment of the EUR 3.5 million in unconditional funding agreed with Atlas...
Nasdaq GlobeNewswire
16/11/2023

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care…

RealizedCare introduces an advanced care management platform powered by DTx technology. The platform's approach, which combines DTx with traditional wraparound services, will unlock value-based chronic pain management at scale. Grünenthal, a global research-based pharmaceutical company and parent company of Fern Health, has partnered with RealizedCare as a strategic investor, delivering on its shared vision of a world free of pain. RealizedCare introduces an advanced care management platform...
PR Newswire
16/11/2023

Hovione acquires ExtremoChem and its portfolio of proprietary sugars to support…

ExtremoChem developed a library of proprietary sugars, synthetic analogues of natural molecules found in extremophiles – organisms capable of withstanding the most uninhabitable environments. These sugars have shown potential in overcoming challenges associated with the stabilization of biopharmaceuticals during production, purification, formulation, and transportation. Dr. Jean-Luc Herbeaux, Hovione's CEO commented: "Proteins and other biopharmaceuticals account for a significant...
PR Newswire
16/11/2023

Groupe Casino - Nombre de droits de vote et d'actions au 31-10-2023

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 165 892 131,90 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2023(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote...
Nasdaq GlobeNewswire
16/11/2023

Amwins Global Risks partners with Blood Cancer UK to raise funds for myeloma

For most people, myeloma responds well to initial treatment but unfortunately it almost always comes back. The money Amwins raises will go towards the Matthew Wilson Multiple Myeloma Fund set up by Matthew and his family with Blood Cancer UK. For most people, myeloma responds well to initial treatment but unfortunately it almost always comes back. The money Amwins raises will go towards the Matthew Wilson Multiple Myeloma Fund set up by Matthew and his family with Blood Cancer UK. Speaking...
PR Newswire
16/11/2023

Kanna Health announces FDA and MHRA approvals to begin its Phase 1 clinical…

The Phase 1 study will be conducted in the UK by Simbec-Orion, an experienced full-service Contract Research Organization (CRO). The Phase 1 study will be conducted in the UK by Simbec-Orion, an experienced full-service Contract Research Organization (CRO). DrRyan Protzko, Kanna Health's President, stated:"Our clinical trial approval on both sides of the Atlantic represents a critical milestone as we officially become a clinical stage company. The study marks the start of a journey...
PR Newswire
16/11/2023

NYU Langone Health to adopt new Philips health technology solutions in…

To unlock patient data for precision diagnosis and treatment, the new partnership includes digital pathology, clinical informatics, and innovative AI-enabled diagnostics with an enterprise monitoring as a service model New York, NY– Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in health technology, and NYU Langone Health, the nation's top-ranked academic medical center, [1] today announced an 8-year strategic partnership valued up to USD 115 million and aimed at enhancing...
Nasdaq GlobeNewswire
16/11/2023

Gastroretentive Drug Delivery Systems Outsourcing Market worth $2.32 Bn by 2031…

Gastroretentive Drug Delivery Systems Outsourcing Market Report Scope Gastroretentive Drug Delivery Systems Outsourcing Market Report Scope Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2154 The gastroretentive drug delivery system represents a novel strategy for drug administration, providing a notable benefit through the extended retention of drugs within the stomach. The phenomenon of longer stomach retention has been observed to...
PR Newswire
16/11/2023

The TAFS conference in Abu Dhabi brings together experts from more than 20…

The control of animal diseases, especially transboundary animal diseases (TAD's), requires cooperation and alignment between all countries in the region. The control of animal diseases, especially transboundary animal diseases (TAD's), requires cooperation and alignment between all countries in the region. Livestock production is one of the most important sources of food security and income in the MENA region and contributes to the livelihoods of millions of people. However, "the...
PR Newswire
16/11/2023

Particle Size Analysis Market Worth $596 Million | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74084833 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=74084833 Browse in-depth TOC on "Particle Size Analysis Market" 116 - Tables 37 - Figures 204 - Pages Particle Size Analysis Market Scope: Laser diffraction segment to register significant growth rate over the forecast period of 2023-2028. Based on the technology, the...
PR Newswire
16/11/2023

Brain Cancer Diagnostics Market is Forecasted to Surge USD 2.5 billion by 2031…

The surge in the prevalence of neurological disorders & cancer owing to the rise in several individuals who smoke is driving the global brain cancer diagnostics industry. This escalating health concern necessitates developing and adopting advanced diagnostic solutions to address these challenges effectively. Rise in awareness and increase in screening programs for brain cancer are the other factors propelling market expansion. Developing more advanced, accurate, and efficient diagnostic…
PR Newswire
16/11/2023

Densitas Unveils intelliMaven™ at RSNA: Your NextGen AI Solution for Mammography…

IntelliMaven™ boosts operational efficiency by transforming complex data into actionable insights in seconds, to mitigate cognitive overload and burnout. This AI-driven, objective, standardized continuous feedback empowers technologists with increased ownership and autonomy in their roles, minimizing disruptions for radiologists and leading to heightened pride and job satisfaction. IntelliMaven™ boosts operational efficiency by transforming complex data into actionable insights in seconds, to...
PR Newswire
16/11/2023

EARTHDAY.ORG RELEASES REPORT BABIES VS. PLASTICS

With over 100+ studies, reports and articles reviewed – BABIES VS. PLASTICS makes for shocking reading: With over 100+ studies, reports and articles reviewed –BABIES VS. PLASTICSmakes for shocking reading: Research suggests thehealth implications presented by microplastics and their additive chemicals extend to children both before and after birth. There's evidence microplastics caninterrupt maternal-fetal communication and potentiallydamage DNA. Some studies report finding...
PR Newswire
16/11/2023

Amolyt Pharma Named 'Biotech Company of the Year' at the LSX European Lifestars…

thin London, U.K. The European Lifestars Awards (ELAs) are an annual event that acknowledges and celebrates the significant achievements within the life sciences sector across Europe. These awards recognize the innovation and ground-breaking achievements of the life sciences industry's most distinguished executive leaders, investors, partners, and dealmakers for their outstanding contributions to the advancement of the industry. The 'Biotech of the Year' award recognizes a company that...
Nasdaq GlobeNewswire
16/11/2023

Endo Announces Five Presentations at the Sexual Medicine Society of North…

The five new Endo-sponsored and Endo-supported presentations are below: The five new Endo-sponsored and Endo-supported presentations are below: About the Post Hoc Phase 3 Data Analysis 1 A post hoc analysis of pooled data from two randomized, double-blind, placebo-controlled Phase 3 trials was conducted to evaluate CCH treatment and improvement in penile curvature in participants presenting with/without penile pain at baseline and disease duration of 12–18 months or >18 months...
PR Newswire
16/11/2023

Inside information: Bioretec's Board of Directors to initiate a new CEO…

"It has been an honor to lead Bioretec since 2019, overseeing the company's dynamic growth with unwavering commitment. I deem that this is an appropriate juncture for a new leader to continue to implement the Company's vision. My deepest appreciation goes out to our executive team, the Board, and our knowledgeable staff, whose collaborative efforts have been integral to our successes in redefining bone fracture treatment and improving patients' quality of life," says Timo Lehtonen, the…
PR Newswire
16/11/2023

TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating…

PARIS, Nov. 16, 2023 /PRNewswire/ -- TB Alliance launched a new Pan-Phase 2 clinical trial incorporating elements of Phase 2a, b and c, identified as NC-009, to evaluate the safety and efficacy of a combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, components of TB Alliance's BPaL regimen. This regimen has the potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis (TB)—one of the world's deadliest infectious diseases…
PR Newswire
16/11/2023

Curium Announces First Patients in Europe Injected With PYLCLARI® – an…

®(INN: Piflufolastat ( 18 F) also known as ( 18F)-DCFPyL, indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:Primary staging of patients with high-risk PCa prior to initial curative therapyTo localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary...
Nasdaq GlobeNewswire
16/11/2023

Lesaffre strengthens its presence in the United States

With the objective to nourish 9 billion human beings by 2050, Lesaffre is investing in both new equipment and R&D to be as close as possible to its customers and offer them the most relevant solutions, while respecting the planet's limited resources. Further expansion inthe United Statesis strategic for Lesaffre, this is why many investments were made in 2023. The 10 thfermentor for the yeast plant inCedar Rapids, Iowa To meet the growing demand in the...
PR Newswire
16/11/2023

SHL Medical achieves EcoVadis® Silver Medal and sets ambitious science-based…

SHL's outstanding EcoVadis® performance evaluation (69/100) reflects the company's commitment and performance across all assessed areas: Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. The result ranks SHL Medical in the top 8% in its industry, "manufacture of medical and dental instruments and supplies", and in the top 25% of all companies globally. SHL's outstanding EcoVadis ®performance evaluation (69/100) reflects the company's commitment and performance…
PR Newswire
16/11/2023

Grifols launches new solution to facilitate pre-transfusion compatibility…

Grifols sCD38's novel approach enables a more seamless screening, identification and crossmatching process when using Grifols' DG Gel system for running pre-transfusion compatibility tests. When using this solution, laboratories have clearer clinical pictures with less effort compared with current alternative solutions. Grifols sCD38's novel approach enables a more seamless screening, identification and crossmatching process when using Grifols' DG Gel system for running pre-transfusion...
PR Newswire
16/11/2023
Altri  Comunicati